Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 18/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451203 | 1.00 | NTRK1 (0.66) | NTRK1PDPK1JAK2INSRIGF1R | |
| SCHEMBL29415511 | 0.88 | NTRK1 (0.52) | NTRK1PDPK1JAK2AURKB | |
| SCHEMBL3512493 | 0.88 | NTRK1 (0.52) | NTRK1PDPK1JAK2AURKB | |
| SCHEMBL29415512 | 0.88 | NTRK1 (0.52) | NTRK1PDPK1JAK2AURKB | |
| SCHEMBL23901370 | 0.83 | NTRK1 (0.64) | NTRK1INSRIGF1RALKAURKA | |
| SCHEMBL3512392 | 0.81 | JAK2 (0.58) | NTRK1PDPK1JAK2AURKAAURKB | |
| SCHEMBL3513208 | 0.80 | SGK1 (0.45) | NTRK1PDPK1JAK2INSRALK | |
| SCHEMBL14177539 | 0.78 | JAK2 (0.55) | NTRK1PDPK1JAK2AURKAAURKB | |
| SCHEMBL3514510 | 0.77 | NTRK1 (0.42) | NTRK1PDPK1JAK2INSRALK | |
| SCHEMBL1336197 | 0.77 | NTRK1 (0.60) | NTRK1PDPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080001-A | Perfluoroalkyl substituted pyrimido [1,2-b ] indazole ketone compound and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-113801062-A | Preparation method of 3-amino-5- (3, 5-difluorobenzyl) -1H-indazole | 沈阳药科大学 | 2021-12-17 | — | — | CN | claimed |
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-09-25 | — | — | US | claimed |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-08 | — | — | US | claimed |
| CN-122080001-A | Perfluoroalkyl substituted pyrimido [1,2-b ] indazole ketone compound and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| CN-115916771-B | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118530239-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-101754956-B | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-04-23 | — | — | CN | disclosed |
| US-8673893-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-18 | — | — | US | disclosed |
| WO-2013174876-A1 | PROCESS FOR THE PREPARATION OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-28 | — | — | WO | disclosed |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | MAP3K19, ABL1, MAP3K20 | NTRK1 1467/4885PDPK1 100/4885JAK2 177/4885 |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | NTRK1 1510/4885PDPK1 59/4885JAK2 187/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | NTRK1 3/4885PDPK1 533/4885JAK2 2121/4885 |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | NTRK1 1510/4885PDPK1 59/4885JAK2 187/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | NTRK1 4/4885PDPK1 2285/4885JAK2 2366/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | NTRK1 3/4885PDPK1 533/4885JAK2 2121/4885 |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | NTRK1 1467/4885PDPK1 100/4885JAK2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.